Bicycle Therapeutics plc (BCYC)

NASDAQ: BCYC · IEX Real-Time Price · USD
23.10
-1.20 (-4.94%)
Jun 14, 2024, 4:00 PM EDT - Market closed
-4.94%
Market Cap 984.81M
Revenue (ttm) 41.61M
Net Income (ttm) -168.16M
Shares Out 42.63M
EPS (ttm) -4.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 169,915
Open 24.13
Previous Close 24.30
Day's Range 22.96 - 24.19
52-Week Range 12.54 - 28.91
Beta 0.88
Analysts Strong Buy
Price Target 47.25 (+104.55%)
Earnings Date Aug 1, 2024

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeti... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 23, 2019
Employees 284
Stock Exchange NASDAQ
Ticker Symbol BCYC
Full Company Profile

Financial Performance

In 2023, BCYC's revenue was $26.98 million, an increase of 86.52% compared to the previous year's $14.46 million. Losses were -$180.66 million, 60.3% more than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BCYC stock is "Strong Buy." The 12-month stock price forecast is $47.25, which is an increase of 104.55% from the latest price.

Price Target
$47.25
(104.55% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...

11 days ago - Business Wire

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...

22 days ago - Business Wire

Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...

22 days ago - Business Wire

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...

6 weeks ago - Business Wire

Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...

7 weeks ago - Business Wire

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...

2 months ago - Business Wire

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...

3 months ago - Business Wire

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...

4 months ago - Business Wire

Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

4 months ago - Business Wire

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p...

6 months ago - Business Wire

Bicycle Therapeutics to Host R&D Day on December 14

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

7 months ago - Business Wire

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...

8 months ago - Business Wire

Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p...

8 months ago - Business Wire

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-...

8 months ago - GlobeNewsWire

Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p...

9 months ago - Business Wire

Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p...

10 months ago - Business Wire

Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...

11 months ago - Business Wire

Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...

11 months ago - Business Wire

Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...

1 year ago - Business Wire

Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...

1 year ago - Business Wire

Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

1 year ago - Business Wire

Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...

1 year ago - Business Wire

Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

1 year ago - Business Wire

Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023

CAMBRIDGE, England & BOSTON & PARIS--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results. Bicycle is pioneer...

1 year ago - Business Wire

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

BERLIN & CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bayer and Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing...

1 year ago - Business Wire